Annual EBITDA
-$27.95 M
+$9.34 M+25.04%
December 31, 2023
Summary
- As of February 8, 2025, AVTX annual EBITDA is -$27.95 million, with the most recent change of +$9.34 million (+25.04%) on December 31, 2023.
- During the last 3 years, AVTX annual EBITDA has risen by +$17.50 million (+38.49%).
- AVTX annual EBITDA is now -295.28% below its all-time high of $14.32 million, reached on December 31, 2017.
Performance
AVTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$12.83 M
-$3.39 M-35.89%
September 30, 2024
Summary
- As of February 8, 2025, AVTX quarterly EBITDA is -$12.83 million, with the most recent change of -$3.39 million (-35.89%) on September 30, 2024.
- Over the past year, AVTX quarterly EBITDA has dropped by -$3.39 million (-35.89%).
- AVTX quarterly EBITDA is now -158.50% below its all-time high of $21.93 million, reached on September 30, 2017.
Performance
AVTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$35.84 M
-$9.12 M-34.12%
September 30, 2024
Summary
- As of February 8, 2025, AVTX TTM EBITDA is -$35.84 million, with the most recent change of -$9.12 million (-34.12%) on September 30, 2024.
- Over the past year, AVTX TTM EBITDA has dropped by -$9.12 million (-34.12%).
- AVTX TTM EBITDA is now -316.10% below its all-time high of $16.58 million, reached on September 30, 2017.
Performance
AVTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AVTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +25.0% | -35.9% | -34.1% |
| 3 y3 years | +38.5% | -45.4% | +3.9% |
| 5 y5 years | -170.1% | -613.1% | +3.9% |
AVTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +65.3% | -410.7% | +38.4% | -72.6% | +55.5% |
| 5 y | 5-year | -106.9% | +65.3% | -410.7% | +57.4% | -165.3% | +55.5% |
| alltime | all time | -295.3% | +65.3% | -158.5% | +57.4% | -316.1% | +55.5% |
Avalo Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$12.83 M(+35.9%) | -$35.84 M(+34.1%) |
| Jun 2024 | - | -$9.44 M(+81.7%) | -$26.72 M(+9.6%) |
| Mar 2024 | - | -$5.20 M(-38.0%) | -$24.39 M(-13.4%) |
| Dec 2023 | -$27.95 M(-25.0%) | -$8.38 M(+125.9%) | -$28.16 M(-1.5%) |
| Sep 2023 | - | -$3.71 M(-47.8%) | -$28.60 M(+37.7%) |
| Jun 2023 | - | -$7.11 M(-20.7%) | -$20.77 M(-18.4%) |
| Mar 2023 | - | -$8.96 M(+1.6%) | -$25.45 M(-31.7%) |
| Dec 2022 | -$37.29 M(-53.7%) | -$8.82 M(-313.6%) | -$37.30 M(-19.2%) |
| Sep 2022 | - | $4.13 M(-135.0%) | -$46.14 M(-30.4%) |
| Jun 2022 | - | -$11.80 M(-43.3%) | -$66.30 M(-6.9%) |
| Mar 2022 | - | -$20.81 M(+17.8%) | -$71.17 M(-11.6%) |
| Dec 2021 | -$80.50 M(+77.1%) | -$17.67 M(+10.3%) | -$80.50 M(+37.0%) |
| Sep 2021 | - | -$16.02 M(-3.9%) | -$58.74 M(+5.7%) |
| Jun 2021 | - | -$16.68 M(-44.6%) | -$55.55 M(+10.5%) |
| Mar 2021 | - | -$30.13 M(-836.1%) | -$50.26 M(+96.8%) |
| Dec 2020 | -$45.45 M(+236.4%) | $4.09 M(-131.9%) | -$25.54 M(-26.5%) |
| Sep 2020 | - | -$12.83 M(+12.7%) | -$34.74 M(+46.5%) |
| Jun 2020 | - | -$11.39 M(+110.5%) | -$23.70 M(+57.7%) |
| Mar 2020 | - | -$5.41 M(+6.0%) | -$15.04 M(+11.3%) |
| Dec 2019 | -$13.51 M | -$5.11 M(+183.8%) | -$13.51 M(+46.6%) |
| Sep 2019 | - | -$1.80 M(-33.9%) | -$9.21 M(-21.2%) |
| Jun 2019 | - | -$2.72 M(-30.0%) | -$11.69 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$3.89 M(+380.8%) | -$11.77 M(+13.7%) |
| Dec 2018 | -$10.35 M(-172.3%) | -$808.20 K(-81.1%) | -$10.35 M(-23.3%) |
| Sep 2018 | - | -$4.27 M(+52.8%) | -$13.49 M(-206.1%) |
| Jun 2018 | - | -$2.80 M(+13.3%) | $12.71 M(-7.5%) |
| Mar 2018 | - | -$2.47 M(-37.5%) | $13.74 M(-4.0%) |
| Dec 2017 | $14.32 M(-189.2%) | -$3.95 M(-118.0%) | $14.32 M(-13.7%) |
| Sep 2017 | - | $21.93 M(-1339.4%) | $16.58 M(-246.8%) |
| Jun 2017 | - | -$1.77 M(-6.6%) | -$11.30 M(-13.2%) |
| Mar 2017 | - | -$1.89 M(+12.7%) | -$13.01 M(-19.0%) |
| Dec 2016 | -$16.05 M(+46.1%) | -$1.68 M(-71.8%) | -$16.05 M(-11.0%) |
| Sep 2016 | - | -$5.96 M(+71.1%) | -$18.04 M(+28.5%) |
| Jun 2016 | - | -$3.48 M(-29.5%) | -$14.04 M(+4.4%) |
| Mar 2016 | - | -$4.94 M(+34.5%) | -$13.44 M(+22.4%) |
| Dec 2015 | -$10.99 M(-35.7%) | -$3.67 M(+87.9%) | -$10.99 M(-1.4%) |
| Sep 2015 | - | -$1.95 M(-32.3%) | -$11.14 M(-26.6%) |
| Jun 2015 | - | -$2.89 M(+16.4%) | -$15.18 M(-4.8%) |
| Mar 2015 | - | -$2.48 M(-35.2%) | -$15.94 M(-6.7%) |
| Dec 2014 | -$17.09 M(+32.3%) | -$3.82 M(-36.2%) | -$17.09 M(+28.8%) |
| Sep 2014 | - | -$5.99 M(+64.2%) | -$13.26 M(+82.4%) |
| Jun 2014 | - | -$3.65 M(+0.7%) | -$7.27 M(+100.7%) |
| Mar 2014 | - | -$3.62 M | -$3.62 M |
| Dec 2013 | -$12.91 M | - | - |
FAQ
- What is Avalo Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Avalo Therapeutics?
- What is Avalo Therapeutics annual EBITDA year-on-year change?
- What is Avalo Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly EBITDA year-on-year change?
- What is Avalo Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Avalo Therapeutics?
- What is Avalo Therapeutics TTM EBITDA year-on-year change?
What is Avalo Therapeutics annual EBITDA?
The current annual EBITDA of AVTX is -$27.95 M
What is the all time high annual EBITDA for Avalo Therapeutics?
Avalo Therapeutics all-time high annual EBITDA is $14.32 M
What is Avalo Therapeutics annual EBITDA year-on-year change?
Over the past year, AVTX annual EBITDA has changed by +$9.34 M (+25.04%)
What is Avalo Therapeutics quarterly EBITDA?
The current quarterly EBITDA of AVTX is -$12.83 M
What is the all time high quarterly EBITDA for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly EBITDA is $21.93 M
What is Avalo Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AVTX quarterly EBITDA has changed by -$3.39 M (-35.89%)
What is Avalo Therapeutics TTM EBITDA?
The current TTM EBITDA of AVTX is -$35.84 M
What is the all time high TTM EBITDA for Avalo Therapeutics?
Avalo Therapeutics all-time high TTM EBITDA is $16.58 M
What is Avalo Therapeutics TTM EBITDA year-on-year change?
Over the past year, AVTX TTM EBITDA has changed by -$9.12 M (-34.12%)